Article requires registration

Continuous Production in the Pharmaceutical Industry Why Will it No Longer be Possible to Work without Continuous Production?

From Anke Geipel-Kern

Continuous production has arrived in the pharmaceutical manufacturing sector and it’s not going away anytime soon. Spurred on by the ever-increasing number of innovative and at the same time very expensive active ingredients, the pharmaceutical industry is relying on technology to reach the market faster and to ensure less wastage of expensive active ingredient used for clinical samples, scale up and release procedures. How are new drugs changing the rules of the game in production?

Related Companies

Continuous multi-purpose platform for the production of tablets from powders.
Continuous multi-purpose platform for the production of tablets from powders.
(Source: Gea)

Continuous production in pharmaceutical manufacturing – long considered a niche technology – is slowly but surely taking over the entire pharmaceutical industry. Since the FDA approved the Vertex preparation Orkambi in 2015 as the first drug produced with continuous direct compression, there is hardly a major international pharmaceutical company that is not involved in continuous production, says Harald Stahl, Head of Innovation & Strategy, at Gea Pharma & Healthcare.

Additional Information
One question – one answer
Harald Stahl, Head of Innovation & Strategy, at Gea Pharma & Healthcare, explains why the draft of ICH Q13 on Continuous Production creates certainty

Harald Stahl, Head of Innovation & Strategy, at Gea Pharma & Healthcare
Harald Stahl, Head of Innovation & Strategy, at Gea Pharma & Healthcare
( Source: Gea )